Literature DB >> 27086175

A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay.

Roopika Menon1, Judith Müller2, Petra Schneider2, Sotirios Lakis2, Kenneth Thress3, Jürgen Wolf4, Lukas Heukamp2, Johannes M Heuckmann2, Frank Griesinger5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27086175     DOI： 10.1016/j.jtho.2016.04.005

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  13 in total

Review 1.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

Authors:  Roberta Minari; Paola Bordi; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Authors:  Joan Rou-En Choo; Chee-Seng Tan; Ross A Soo
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

3.  Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.

Authors:  Elisa DE Carlo; Monica Schiappacassi; Giacomo Pelizzari; Tania Baresic; Alessandro Del Conte; Brigida Stanzione; Valentina DA Ros; Roberto Doliana; Gustavo Baldassarre; Alessandra Bearz
Journal:  In Vivo       Date:  2021 Sep-Oct       Impact factor: 2.155

4.  Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.

Authors:  Anna Buder; Ellen Heitzer; Julie Waldispühl-Geigl; Sabrina Weber; Tina Moser; Maximilian J Hochmair; Klaus Hackner; Peter Errhalt; Ulrike Setinek; Martin Filipits
Journal:  Biomolecules       Date:  2021-04-21

Review 5.  Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.

Authors:  Jing Xu; Jinghui Wang; Shucai Zhang
Journal:  Oncotarget       Date:  2017-09-22

Review 6.  [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].

Authors:  Lianfang Ni; Ligong Nie
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-02-20

Review 7.  [Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].

Authors:  Zitong Zhao; Yu Ni; Li Li; Tao Xin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-04-20

Review 8.  Third generation EGFR TKIs: current data and future directions.

Authors:  Chee-Seng Tan; Nesaretnam Barr Kumarakulasinghe; Yi-Qing Huang; Yvonne Li En Ang; Joan Rou-En Choo; Boon-Cher Goh; Ross A Soo
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

9.  Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.

Authors:  Keke Nie; Haiping Jiang; Chunling Zhang; Chuanxin Geng; Xiajuan Xu; Ling Zhang; Hao Zhang; Zhongfa Zhang; Ketao Lan; Youxin Ji
Journal:  Biomed Res Int       Date:  2018-03-11       Impact factor: 3.411

Review 10.  The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.

Authors:  Yi-Chen Zhang; Qing Zhou; Yi-Long Wu
Journal:  J Hematol Oncol       Date:  2017-10-23       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.